Emerging role of natural products in cancer immunotherapy.
Acta Pharm Sin B
; 12(3): 1163-1185, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-35530162
AKT, alpha-serine/threonine-specific protein kinase; Adoptive immune-cells transfer immunotherapy; B2M, beta-2-microglobulin; BMDCs, bone marrow dendritic cells; BPS, basil polysaccharide; BTLA, B- and T-lymphocyte attenuator; CAFs, cancer-associated fibroblasts; CCL22, CC motif chemokine 22; CIKs, cytokine-induced killer cells; COX-2, cyclooxygenase-2; CRC, colorectal cancer; CTL, cytotoxic T cell; CTLA-4, cytotoxic T lymphocyte antigen-4; Cancer immunotherapy; Cancer vaccines; DAMPs, damage-associated molecular patterns; DCs, dendritic cells; FDA, US Food and Drug Administration; HCC, hepatocellular carcinoma; HER-2, human epidermal growth factor receptor-2; HIF-1α, hypoxia-inducible factor-1α; HMGB1, high-mobility group box 1; HSPs, heat shock proteins; ICD, Immunogenic cell death; ICTs, immunological checkpoints; IFN-γ, interferon γ; IL-10, interleukin-10; Immuno-check points; Immunosuppressive microenvironment; LLC, Lewis lung cancer; MDSCs, myeloid-derived suppressor cells; MHC, major histocompatibility complex class; MITF, melanogenesis associated transcription factor; MMP-9, matrix metalloprotein-9; Mcl-1, myeloid leukemia cell differentiation protein 1; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NKTs, natural killer T cells; NSCLC, non-small cell lung cancer; Natural products; OVA, ovalbumin; PD-1, programmed death-1; PD-L1, programmed death receptor ligand 1; PGE-2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TAMs, tumor-associated macrophages; TAP, transporters related with antigen processing; TGF-ß, transforming growth factor-ß; TILs, tumor infiltration lymphocytes; TLR, Toll-like receptor; TNF-α, tumor necrosis factor α; TSA, tumor specific antigens; Teffs, effective T cells; Th1, T helper type 1; Tregs, regulatory T cells; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; mTOR, mechanistic target of rapamycin
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article